ANI Pharmaceuticals (NASDAQ:ANIP) Price Target Raised to $65.00 at Truist Financial

ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) had its target price hoisted by Truist Financial from $62.00 to $65.00 in a report issued on Monday morning,Benzinga reports. Truist Financial currently has a hold rating on the specialty pharmaceutical company's stock.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reissued a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a "buy" rating and a $80.00 price target on the stock. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price objective for the company. Guggenheim reiterated a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. Finally, StockNews.com raised ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, April 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock traded down $0.64 during mid-day trading on Monday, reaching $69.00. 23,439 shares of the company were exchanged, compared to its average volume of 271,474. The firm's 50-day simple moving average is $64.02 and its two-hundred day simple moving average is $59.75. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.48. The firm has a market cap of $1.50 billion, a PE ratio of -125.63 and a beta of 0.49. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now owns 80,545 shares of the company's stock, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,200 shares of company stock valued at $197,792. 12.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ANIP. Millennium Management LLC raised its position in shares of ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after buying an additional 473,097 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after purchasing an additional 340,854 shares during the period. abrdn plc purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter worth $13,155,000. Deep Track Capital LP grew its position in shares of ANI Pharmaceuticals by 28.6% in the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after purchasing an additional 144,214 shares during the period. Finally, Barclays PLC grew its position in shares of ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock valued at $8,534,000 after purchasing an additional 135,003 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.